The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2024 | Promising clinical efficacy of mitazalimab + mFOLFIRINOX for advanced pancreatic cancer
Karen Geboes, MD, PhD, UZ Ghent – University Hospital Gent, Gent, Belgium, shares her excitement for the promising preliminary results from the Phase Ib/II OPTIMIZE-1 trial (NCT04888312) of mitazalimab and modified FOLFIRINOX for metastatic pancreatic cancer. The advent of a Phase III trial in the future could confirm and demonstrate the superiority of this combination therapy compared to standard treatment to increase progression-free survival (PFS) and improve patient quality of life. This interview took place at the 39th Annual Meeting of the Society for Immunotherapy of Cancer 2024, Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
